If a potential multi-organ donor is HepC virus antibody-reactive, what should the procurement coordinator offer?

If a potential multi-organ donor is HepC virus antibody-reactive, what should the procurement coordinator offer?

• A. All organs except liver
• B. All organs for transplantation
• C. Organ for urgent patients only
• D. The kidneys for HCV reactive patients

Answer: (B)

When a potential multi-organ donor is Hepatitis C virus (HCV) antibody-reactive, procurement practices suggest that all organs can still be offered for transplantation. This is based on the understanding of current transplantation practices, which have evolved to account for the efficiency and safety of organ transplantation from HCV-positive donors. By offering all organs for transplantation, the procurement coordinator is acknowledging that recipients can be screened and given appropriate treatment for HCV, especially since the effective antiviral therapies available today allow for successful management of the virus in transplant recipients. This approach can help to address the organ shortage crisis by increasing the pool of available organs. Recipient selection plays a critical role; individuals who are already living with HCV can potentially benefit from transplantation without the risks associated with uninfected organs. Additionally, advancements in medicine have made it possible for patients who are at risk to undergo treatment post-transplant, contributing to successful outcomes. The other options, while seemingly cautious, do not support the best practices currently recommended in the field. Offering limited organs or only specific organs may not maximize the potential donor organs available to patients in need and does not take full advantage of advancements in managing HCV in transplant recipients.

When a potential multi-organ donor is Hepatitis C virus (HCV) antibody-reactive, procurement practices suggest that all organs can still be offered for transplantation. This is based on the understanding of current transplantation practices, which have evolved to account for the efficiency and safety of organ transplantation from HCV-positive donors.

By offering all organs for transplantation, the procurement coordinator is acknowledging that recipients can be screened and given appropriate treatment for HCV, especially since the effective antiviral therapies available today allow for successful management of the virus in transplant recipients. This approach can help to address the organ shortage crisis by increasing the pool of available organs.

Recipient selection plays a critical role; individuals who are already living with HCV can potentially benefit from transplantation without the risks associated with uninfected organs. Additionally, advancements in medicine have made it possible for patients who are at risk to undergo treatment post-transplant, contributing to successful outcomes.

The other options, while seemingly cautious, do not support the best practices currently recommended in the field. Offering limited organs or only specific organs may not maximize the potential donor organs available to patients in need and does not take full advantage of advancements in managing HCV in transplant recipients.